Cargando…

Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug–Drug Interaction Potential of Siponimod With Physiologically‐Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations

We predicted the drug–drug interaction (DDI) potential of siponimod in presence of cytochrome P450 (CYP)2C9/CYP3A4 inhibitors/inducers in subjects with different CYP2C9 genotypes by physiologically‐based pharmacokinetic (PK) modeling. The model was established using in vitro and clinical PK data and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huth, Felix, Gardin, Anne, Umehara, Kenichi, He, Handan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6851657/ https://www.ncbi.nlm.nih.gov/pubmed/31199498 http://dx.doi.org/10.1002/cpt.1547

Ejemplares similares

A comprehensive evaluation in clinic and physiologically‐based pharmacokinetic modeling and simulation to confirm lack of cytochrome P450–mediated drug–drug interaction potential for pomotrelvir
por: Yang, Ziping, et al.
Publicado: (2023)

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of a Drug–Drug Interaction of Combined Effects on P‐glycoprotein and Cytochrome P450 3A
por: Otsuka, Yukio, et al.
Publicado: (2020)

Role of cytochrome P450 genotype in the steps toward personalized drug therapy
por: Cavallari, Larisa H, et al.
Publicado: (2011)

Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2008)

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
por: Johansson, Susanne, et al.
Publicado: (2017)

Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam
por: Perkins, Everett J., et al.
Publicado: (2017)

Assessment of cytochrome P450 3A4-mediated drug–drug interactions for ipatasertib using a fit-for-purpose physiologically based pharmacokinetic model
por: Jing, Jing, et al.
Publicado: (2022)

Effects of mistletoe products on pharmacokinetic drug turnover by inhibition and induction of cytochrome P450 activities
por: Schink, Michael, et al.
Publicado: (2017)

Retraction: Role of cytochrome P450 in drug interactions
por: Bibi, Zakia
Publicado: (2014)

Cytochrome P450 Enzymes and Drug Metabolism in Humans
por: Zhao, Mingzhe, et al.
Publicado: (2021)

Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo
por: Wang, Yiran, et al.
Publicado: (2020)

In Silico Prediction of Drug–Drug Interactions Mediated by Cytochrome P450 Isoforms
por: Dmitriev, Alexander V., et al.
Publicado: (2021)

The Development and Validation of a Novel “Dual Cocktail” Probe for Cytochrome P450s and Transporter Functions to Evaluate Pharmacokinetic Drug-Drug and Herb-Drug Interactions
por: Kwon, Mihwa, et al.
Publicado: (2020)

Physiologically‐Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug–Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations
por: Taskar, Kunal S., et al.
Publicado: (2019)

Deuterium isotope effects in drug pharmacokinetics II: Substrate-dependence of the reaction mechanism influences outcome for cytochrome P450 cleared drugs
por: Sun, Hao, et al.
Publicado: (2018)

Drug-drug interaction of acetaminophen and roxithromycin with the cocktail of cytochrome P450 and hepatotoxicity in rats
por: Liu, Xiang, et al.
Publicado: (2020)

Prediction of cytochromes P450 3A and 2C19 modulation by both inflammation and drug interactions using physiologically based pharmacokinetics
por: Lenoir, Camille, et al.
Publicado: (2021)

Use of Drugs that Act on the Cytochrome P450 System in the Elderly
por: Cabrera, Marcos A S, et al.
Publicado: (2009)

Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children
por: Aka, Ida, et al.
Publicado: (2017)

Comprehensive Physiologically Based Pharmacokinetic Model to Assess Drug–Drug Interactions of Phenytoin
por: Rodriguez-Vera, Leyanis, et al.
Publicado: (2023)

A generic framework for the physiologically‐based pharmacokinetic platform qualification of PK‐Sim and its application to predicting cytochrome P450 3A4–mediated drug–drug interactions
por: Frechen, Sebastian, et al.
Publicado: (2021)

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
por: Gardin, Anne, et al.
Publicado: (2018)

Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults
por: Armani, Sara, et al.
Publicado: (2017)

African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development
por: Rajman, Iris, et al.
Publicado: (2017)

Physiologically based pharmacokinetic modeling to assess metabolic drug–drug interaction risks and inform the drug label for fedratinib
por: Wu, Fan, et al.
Publicado: (2020)

Comparative Cytochrome P450 In Vitro Inhibition by Atypical Antipsychotic Drugs
por: Gervasini, Guillermo, et al.
Publicado: (2013)

An update on the role of intestinal cytochrome P450 enzymes in drug disposition
por: Xie, Fang, et al.
Publicado: (2016)

Effect of health foods on cytochrome P450-mediated drug metabolism
por: Sasaki, Takamitsu, et al.
Publicado: (2017)

A history of the roles of cytochrome P450 enzymes in the toxicity of drugs
por: Guengerich, F. Peter
Publicado: (2020)

Inflammatory signaling on cytochrome P450-mediated drug metabolism in hepatocytes
por: Wang, Xiaokang, et al.
Publicado: (2022)

Effects of cytochrome P450 oxidoreductase genotypes on the pharmacokinetics of amlodipine in healthy Korean subjects
por: Han, Ji Min, et al.
Publicado: (2020)

Pharmacokinetic drug interactions of asciminib with the sensitive cytochrome P450 probe substrates midazolam, warfarin, and repaglinide in healthy participants
por: Hoch, Matthias, et al.
Publicado: (2022)

Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design
por: Sun, Hao, et al.
Publicado: (2011)

Potential Cytochrome P450 Drug-Drug Interaction Among Adult and Adolescent Patients Undergoing Tonsillectomy
por: Nimmagadda, Sai, et al.
Publicado: (2020)

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein
por: Zahir, Hamim, et al.
Publicado: (2020)

First in vivo fluorine-19 magnetic resonance imaging of the multiple sclerosis drug siponimod
por: Starke, Ludger, et al.
Publicado: (2023)

Pre-clinical drug-drug interaction (DDI) of gefitinib or erlotinib with Cytochrome P450 (CYP) inhibiting drugs, fluoxetine and/or losartan
por: Luong, Thu-Lan T., et al.
Publicado: (2021)

Short-Term Fasting Alters Pharmacokinetics of Cytochrome P450 Probe Drugs: Does Protein Binding Play a Role?
por: Lammers, Laureen A., et al.
Publicado: (2017)

CRISPR knockout rat cytochrome P450 3A1/2 model for advancing drug metabolism and pharmacokinetics research
por: Lu, Jian, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vv8dh5n329lt6sbfhi5a1vcqu5